New test could unlock precision treatment for tough breast cancers
NCT ID NCT05340413
Summary
This study tested whether a specific lab test, called the RAD51-foci score, could predict which patients with advanced HER2-negative breast cancer would benefit most from the drug olaparib. It involved 65 patients, some with known genetic mutations and some without, to see if the test could identify good candidates for the drug beyond just genetic testing. The goal was to find a better way to match the right patients to this targeted therapy to help control their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H Clinic de Barcelona
Barcelona, Spain
-
H Vall d Hebron
Barcelona, Spain
-
H. 12 de Octubre
Madrid, Spain
-
H. C. U. Valencia
Valencia, Spain
-
H. San Cecilio
Granada, Spain
Conditions
Explore the condition pages connected to this study.